FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Gibson Christopher 2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [ RXRX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)
C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)
8/4/2022
(Street)
SALT LAKE CITY, UT 84101
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock  8/4/2022    M(1)    31250  A $2.48  560154  D   
Class A Common Stock  8/4/2022    S(1)    18325  D $9.5259 (2) 541829  D   
Class A Common Stock  8/4/2022    C(1)(3)    18500  A $0.00  560329  D   
Class A Common Stock  8/4/2022    S(1)    18500  D $9.4529 (4) 541829  D   
Class A Common Stock  8/4/2022    C(1)(3)    500  A $0.00  500  I  by LAHWRAN-3 LLC (5)
Class A Common Stock  8/4/2022    S(1)    500  D $9.4442 (6) 0  I  by LAHWRAN-3 LLC (5)
Class A Common Stock  8/4/2022    C(1)(3)    1000  A $0.00  1000  I  by LAHWRAN-4 LLC (7)
Class A Common Stock  8/4/2022    S(1)    1000  D $9.4477 (8) 0  I  by LAHWRAN-4 LLC (7)
Class A Common Stock  8/4/2022    C(1)(3)    1000  A $0.00  1000  I  by Gibson Family Trust (9)
Class A Common Stock  8/4/2022    S(1)    1000  D $9.447 (10) 0  I  by Gibson Family Trust (9)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock  $0.00  8/4/2022    C (1)(3)       18500    (11)  (11) Class A Common Stock  18500  $0.00  6751334  D   
Stock Option (Right to Buy)  $11.40                   (12) 2/4/2032  Class A Common Stock  0    416350  D   
Stock Option (Right to Buy)  $11.40                  2/4/2022  2/4/2032  Class A Common Stock  0    5436  D   
Stock Option (Right to Buy)  $2.48  8/4/2022    M (1)       31250    (13) 12/30/2030  Class A Common Stock  31250  $0.00  918886  D   
Class B Common Stock  $0.00  8/4/2022    C (1)(3)       500    (11)  (11) Class A Common Stock  500  $0.00  542500  I  by LAHWRAN-3 LLC (5)
Class B Common Stock  $0.00  8/4/2022    C (1)(3)       1000    (11)  (11) Class A Common Stock  1000  $0.00  535000  I  by LAHWRAN-4 LLC (7)
Class B Common Stock  $0.00  8/4/2022    C (1)(3)       1000    (11)  (11) Class A Common Stock  1000  $0.00  131875  I  by Gibson Family Trust (9)

Explanation of Responses:
(1)  Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
(2)  This transaction was executed in multiple trades at prices ranging from $9.51 to $9.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(3)  Represents the conversion of Class B Common Stock into Class A Common Stock.
(4)  This transaction was executed in multiple trades at prices ranging from $9.24 to $9.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(5)  The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
(6)  This transaction was executed in multiple trades at prices ranging from $9.26 to $9.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(7)  The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
(8)  This transaction was executed in multiple trades at prices ranging from $9.27 to $9.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(9)  The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
(10)  This transaction was executed in multiple trades at prices ranging from $9.24 to $9.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
(11)  Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
(12)  The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
(13)  The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Gibson Christopher
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY, UT 84101		 X
Chief Executive Officer

Signatures
/s/ Nathan Hatfield, attorney-in-fact 8/5/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Recursion Pharmaceuticals Charts.
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Recursion Pharmaceuticals Charts.